Ruxolitinib in the Treatment of Covid-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2020-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The treatment of COVID-19 severe acute respiratory syndrome with ruxolitinib 5 mg orally every 12 hours during 14 days would stop the disproportionate inflammatory response, causing a reduction in the proportion of patients who show a progression and worsening of the severe acute respiratory syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006

Aplastic Anemia Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm +4 more

COMPLETED PHASE1

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

NCT04452474

COVID-19

WITHDRAWN PHASE2/PHASE3

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

NCT05438602

COVID-19

COMPLETED PHASE2

Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)

NCT04394884

COVID-19

WITHDRAWN

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

NCT04487574

SARS-CoV-2 Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective

Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome by means of measuring the proportion of patients with clinical worsening (defined by a requirement of FIO2 50% and/or mechanical respiratory assistance) during 14 days after the commencement of treatment.

Secondary Objectives

1. Evaluate the median duration of hospitalization. Median duration after 45 days of commencement of treatment.
2. Evaluate the evolution of systemic inflammation parameters. Evaluation at the beginning (baseline), middle and end of the treatment with ruxolitinib of PCR, LDH, ESD, Ferritin and IL-6.
3. Evaluate COVID-19 mortality rate after 45 days of treatment.
4. Evaluate the proportion of the requirement of mechanical ventilation.
5. Evaluate ruxolitinib adverse reactions with a total follow-up of 45 days.
6. Evaluate the proportion of secondary infections during the treatment with ruxolitinib.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Experimental, open-label, prospective, single center, add-on (added to the standard treatment) study, compared with an historical control arm.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INC424 / Ruxolitinib

1. Ruxolitinib 5 mg orally every 12 hours during 14 days.
2. Total Follow-up time will be of 45 days.
3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.
4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45
5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.
6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.
7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)
8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.
9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jakavi

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients ≥ 18 years.
2. SARS-Cov2 infection confirmed by a validated method.
3. Presence of COVID-19 severe acute respiratory syndrome with:

Respiratory rate ≥ 20/min O2 saturation ≤93% with FiO2 of 0.21 Lung images by means of computerized tomography or thorax radiography compatible with respiratory involvement due to COVID-19.
4. Signed informed consent.

Exclusion Criteria

1. Pregnancy or breast-feeding.
2. Platelets \< 50,000/mm3.
3. Neutrophils \< 1,000/mm3.
4. Hemoglobin \< 6 g/dl
5. Creatinine ≥2 mg/dl or creatinine clearance ≤30 ml/min.
6. Total serum bilirubin \> 2.0 x upper limit of normal and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5 times the upper limit of normal.
7. Known active infection due to HIV, HVC, HVB, Herpes Zoster or Micob Tuberculosis
8. Treatment with Tocilizumab, Baricitinib or Interferon.
9. History of hypersensitivity to ruxolitinib or to any medicine with similar chemical compounds
10. Patients with mechanical respiratory assistance
11. Patients under treatment with Ruxolitinib due to hematological disease
12. Any condition that, according to the Investigator, may interfere with the complete participation of the patient in the study, including the administration of the medicinal product, the limitation of visits, the implication of a risk for the patient or that prevents the correct interpretation of the results.

Treatment Suspension Criteria

1. Voluntary decision of the patient
2. Treating physician's decision to discontinue the treatment
3. Drug toxicity grade 3 or higher (CTCAE 5.0).

Study Design

Experimental, open-label, prospective, single center, add-on (added to the standard treatment) study, compared with the historical control arm.

Control arm: It will include patients with COVID-19 Respiratory Syndrome who meet the aforementioned selection criteria and have received the standard of care (SOC). Efforts will be made so that both arms share similar demographic characteristics as regards gender and age group. Ten centers will participate, which will share the same protocol and their results may be jointly analyzed. The expected n per center is 10-15 patients.

For the safety assessment as part of the objective, the following parameters will be taken into account:

1. Biochemical changes: (day 1, 8 and 14) Leukocytes, Formula, Hemoglobin, platelets, creatinine, glycemia, PT, Bilirubin, GOT/GPT.
2. Grade 3/4 Toxicity, SAE (Serious Adverse Event)
3. Incidence of discontinuation, suspension or dose-reduction of the study drug.
4. Incidence of secondary infections.

Efficacy Assessment:

1. Efficacy will be graded according to the ordinal scale of 8 points.
2. Time to Improvement
3. Time of response consolidation
4. Changes in NEWS table

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No